The controlled release of tilmicosin from silica nanoparticles

Drug Dev Ind Pharm. 2011 Jun;37(6):714-8. doi: 10.3109/03639045.2010.538059. Epub 2011 Jan 5.

Abstract

The aim of this study was to use silica nanoparticles as the carrier for controlled release of tilmicosin. Tilmicosin was selected as a drug model molecule because it has a lengthy elimination half-life and a high concentration in milk after subcutaneous administration. Three samples of tilmicosin-loaded silica nanoparticles were prepared with different drug-loading weight. The drug-loading weight in three samples, as measured by thermal gravimetric analysis, was 29%, 42%, and 64%, respectively. With increased drug-loading weight, the average diameter of the drug-loaded silica nanoparticles was increased from 13.4 to 25.7 nm, and the zeta potential changed from-30.62 to-6.78 mV, indicating that the stability of the drug-loaded particles in the aqueous solution decreases as drug-loading weight increases. In vitro release studies in phosphate-buffered saline showed the sample with 29% drug loading had a slow and sustained drug release, reaching 44% after 72 h. The release rate rose with increased drug-loading weight; therefore, the release of tilmicosin from silica nanoparticles was well-controlled by adjusting the drug loading. Finally, kinetics analysis suggested that drug released from silica nanoparticles was mainly a diffusion-controlled process.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / chemistry
  • Delayed-Action Preparations
  • Diffusion
  • Drug Stability
  • Kinetics
  • Nanoparticles*
  • Particle Size
  • Silicon Dioxide / chemistry*
  • Thermogravimetry
  • Time Factors
  • Tylosin / administration & dosage
  • Tylosin / analogs & derivatives*
  • Tylosin / chemistry

Substances

  • Anti-Bacterial Agents
  • Delayed-Action Preparations
  • Silicon Dioxide
  • tilmicosin
  • Tylosin